10/07/2021 STAT: Backed with $500 million, a startup aims to rethink psychiatric drug development Read More
10/07/2021 Endpoints: ARCH unveils its Really Big Neuroscience Company with $500M, an Amgen deal and eyes on depression, Alzheimer’s and a lot more Read More
10/07/2021 Business Insider: A new startup created by one of biotech’s biggest VCs shows you need to go big to treat brain disorders Read More
10/07/2021 Biopharma Dive: Armed with half a billion dollars, a startup aims to change how brain drugs are made Read More
10/07/2021 Timmerman Report: Neumora Secures $500M, Amgen Deal, in Quest for Neuroscience R&D Read More
10/07/2021 Boston Globe: Neumora hopes to bring precision medicine to brain disease treatments Read More
10/07/2021 Boston Business Journal: Psychiatric drug startup launches with $500M, Amgen partnership Read More
10/07/2021 Chemical & Engineering News: Neumora launches with $500 million to develop drugs for brain diseases Read More
10/07/2021 FierceBiotech: Meet Neumora, Arch’s $500M, Amgen-partnered play for the targeted future of neuroscience R&D Read More